Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
“The amygdala’s response to social threat appears to feed into depressive symptoms much more strongly in young males than in young females.” — John Krystal, MD, Biological Psychiatry
Psychiatry April 14th 2026
Psych Congress Network
Note that many questions remain after this trial returned results that are not unequivocally positive. The prespecified primary outcome was negative, which limits claims of efficacy and argues against overinterpreting the study as confirmatory evidence for psilocybin in treatment-resistant depression.
Clinical Pharmacology April 14th 2026
British Medical Journal (The BMJ)
“Selecting a GLP-1 receptor agonist over another antihyperglycemic drug could plausibly confer ancillary benefit” in patients at high risk for or living with an SUD. — Study authors
Endocrinology, Diabetes, Metabolism March 18th 2026
The Canadian Journal of Psychiatry
“The prevalence of internalizing problems increased more rapidly among Canadians who used cannabis compared to those who do not.” — Study authors
Psychiatry March 18th 2026
Psychiatrist.com
The objective of the study was to characterize the real-world safety profile of TMS devices based on MAUDE-reported AEs, including symptom patterns, manufacturer-level variations, device issues, and reporting delays.
Psychiatry March 4th 2026
“TRD patients have extremely limited treatment options, and the unmet need remains profound.” — Guy Goodwin, MD, CMO, Compass Pathways